Lymphocyte-predominant triple-negative breast carcinomas in premenopausal patients: Lower expression of basal immunohistochemical markers

Imagem de Miniatura
Arquivos
art_MASILI-OKU_Lymphocytepredominant_triplenegative_breast_carcinomas_in_premenopausal_patients_Lower_2017.PDF (1.07 MB)
Citações na Scopus
10
Tipo de produção
article
Data de publicação
2017
Editora
CHURCHILL LIVINGSTONE
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
ALMEIDA, Bernardo Gomes Lacerda de
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
BREAST, v.31, Special Issue, p.34-39, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objectives: Triple-negative breast carcinomas (TNBCs) correspond to a molecular heterogeneous disease defined by lack of estrogen and progesterone receptor expression, and the absence of overexpression and/or amplification of HER2. Recent data indicate that clinical outcome in TNBC is affected by tumorinfiltrating lymphocytes, suggesting that they can benefit from immunotherapies. We selected 116 consecutive premenopausal patients with TNBC to compare the immunohistochemical profile of the group rich in tumor-infiltrating lymphocytes with those without this characteristic. Materials and methods: We reviewed all the original histological sections to assess pathological features, and to select a representative area for tissue microarrays and immunohistochemical study. Estrogen and progesterone receptors, HER2 and Ki-67 were evaluated in whole histological sections. The following markers were analyzed in tissue microarrays sections: androgen receptor, cytokeratin 5/6, cytokeratin 14, epidermal growth factor receptor (EGFR), vimentin, p16, claudin-3, -4, and -7, p63, and aldehyde dehydrogenase isoform 1 (ALDH1). Lymphocyte-predominant breast cancer (LPBC) was defined by the presence of more than 50% of lymphocytes in the intratumoral stroma. Results: Twenty-six (22.4%) patients present tumors classified as LPBC and 90 (77.6%) as non-LPBC. The two groups were similar regarding age of patients, tumor grade and Ki-67 positive cells. LPBC cases presented lower frequency of expression of the basal cytokeratins, EGFR, and basal-like immunoprofile. There was a trend to higher expression of ALDH1 by stromal intratumoral cells. The expression of all other markers were similar in the two groups. Conclusions: Lymphocyte-predominant TNBC in premenopausal patients are mostly of non-basal phenotype.
Palavras-chave
Breast cancer, Triple-negative, Basal-like carcinoma, Tumor-infiltrating lymphocytes, Immunohistochemistry
URI
https://observatorio.fm.usp.br/handle/OPI/17933
Referências
  1. Anders CK, 2011, J CLIN ONCOL, V29, pE18, DOI 10.1200/JCO.2010.28.9199
  2. Bednarz-Knoll N, 2015, ONCOTARGET, V6, P26789, DOI 10.18632/oncotarget.4628
  3. Cancello G, 2010, ANN ONCOL, V21, P1974, DOI 10.1093/annonc/mdq072
  4. Carvalho FM, 2010, CLINICS, V65, P1033, DOI 10.1590/S1807-59322010001000019
  5. Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658
  6. Choi JE, 2015, ANN SURG ONCOL, V22, P82, DOI 10.1245/s10434-014-3984-z
  7. Choi J, 2012, HISTOL HISTOPATHOL, V27, P1481
  8. Denkert C, 2015, J CLIN ONCOL, V33, P983, DOI 10.1200/JCO.2014.58.1967
  9. Elsawaf Z, 2013, BREAST, V22, P986, DOI 10.1016/j.breast.2013.05.012
  10. ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
  11. Gasparini P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088525
  12. Hirshfield KM, 2014, CURR OPIN OBSTET GYN, V26, P34, DOI 10.1097/GCO.0000000000000038
  13. Ibrahim EM, 2014, BREAST CANCER RES TR, V148, P467, DOI 10.1007/s10549-014-3185-2
  14. Inanc M, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0801-7
  15. Keegan THM, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3156
  16. Khoury T, 2012, MODERN PATHOL, V25, P388, DOI 10.1038/modpathol.2011.172
  17. Lakhani SR, 2012, WHO CLASSIFICATION T
  18. Lee HJ, 2015, BREAST CANCER RES TR, V151, P619, DOI 10.1007/s10549-015-3438-8
  19. Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
  20. Liu YR, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0690-8
  21. Liu ZB, 2009, TUMORI, V95, P53
  22. Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112
  23. Malorni L, 2012, BREAST CANCER RES TR, V136, P795, DOI 10.1007/s10549-012-2315-y
  24. Malyuchik S. S., 2008, Experimental Oncology, V30, P96
  25. Mao Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115103
  26. Nassar A, 2012, BREAST J, V18, P399, DOI 10.1111/j.1524-4741.2012.01279.x
  27. Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220
  28. Prat A, 2013, ONCOLOGIST, V18, P123, DOI 10.1634/theoncologist.2012-0397
  29. Pruneri G, 2016, ANN ONCOL, V27, P249, DOI 10.1093/annonc/mdv571
  30. Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450
  31. Tsutsumi Y, 2012, JPN J CLIN ONCOL, V42, P375, DOI 10.1093/jjco/hys034
  32. Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984
  33. Yamamoto Y, 2009, BREAST CANCER-TOKYO, V16, P260, DOI 10.1007/s12282-009-0150-8
  34. Yamashita N, 2013, J CANCER RES CLIN, V139, P739, DOI 10.1007/s00432-013-1376-6

Coleções
Artigos e Materiais de Revistas Científicas - FM/MOG
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - LIM/58
Carregar mais